Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,058 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04668339
Conditions
Covid19, SARS-CoV Infection, Corona Virus Infection
Interventions
ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming, Placebo (two doses), priming, Randomized booster, Placebo booster
Biological
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • San Diego, California + 9 more
Conditions
Crohn's Disease, IBD
Interventions
Brazikumab low dose, Brazikumab high dose, Humira®, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Vitamin D in Postmenopausal Women at High Risk for Breast Cancer

NCT00859651
Conditions
Breast Cancer
Interventions
Cholecalciferol, Placebo capsule
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Covid19
Interventions
SCTA01, Placebo
Drug · Other
Lead sponsor
Sinocelltech Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Somers Point, New Jersey
Not listed Not applicable Interventional Accepts healthy volunteers

Lithium Water in Gun Violence Prevention

NCT02213614
Conditions
Assault by Handgun Discharge, Violence, Homicide, Sexual Assault by Bodily Force, Substance Abuse Problem
Interventions
Lithium Water, placebo: spring mineral water, natural spring water
Dietary Supplement · Other
Lead sponsor
American Society Of Thermalism And Climatology Inc
Other
Eligibility
14 Years to 60 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Ulcerative Colitis
Interventions
Rosnilimab, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Garden Grove, California • Lancaster, California + 20 more
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Suvankar Majumdar
Other
Eligibility
4 Years to 21 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Hypercholesterolemia
Interventions
LY3015014, Placebo, Statin, Ezetimibe
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Encino, California • Lancaster, California • Spring Valley, California + 12 more
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Completed Phase 2 Interventional Results available

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

NCT03655691
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
Vehicle, botulinum toxin, Type A
Biological
Lead sponsor
Eirion Therapeutics Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 3 more
Conditions
Heart Failure
Interventions
Tolvaptan, placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Non-Diabetic
Interventions
REMD-477 versus Placebo, Exogenous glucagon versus saline infusion
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Hallucinations, Auditory, Psychosis
Interventions
Rivastigmine Transdermal System, Scopolamine, Placebo Patch
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

Berberine Supplementation, Sprint Interval Training, and Immune Function Study

NCT07480018
Conditions
Berberine, Sprint Training, Wellbeing, Anaerobic Power, Inflammation Biomarkers, Monocyte Function
Interventions
Berberine, Placebo, Sprint Interval Training
Dietary Supplement · Other
Lead sponsor
University of Northern Colorado
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Greeley, Colorado
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
QAX028, Tiotropium, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Anaheim, California • Normal, Illinois • Spartanburg, South Carolina + 1 more
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD4076, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Conditions
Ulcerative Colitis
Interventions
IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years to 80 Years
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
76
States / cities
Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional and Contractile Regulation of Muscle Growth

NCT00891696
Conditions
Sarcopenia
Interventions
Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff
Drug · Other · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
thrombomodulin alfa, Placebo
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Beverly Hills, California • Los Angeles, California • Norwich, Connecticut + 15 more
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Placebo Comparator, insulin detemir
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more